Physician profile
James E Chlebowski
NPI 1639118458
$5,672.14
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $1,614 · 2021: $1,821 · 2022: $115 · 2023: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $373.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $774.93 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $461.28 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $448.71 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.84 | 2019-2023 | Stiolto Respimat |
| Amgen INC. | $437.27 | 2019-2021 | |
| Pfizer INC. | $420.07 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $365.81 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $344.50 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $326.32 | 2019-2021 | |
| Allergan, INC. | $203.81 | 2019-2020 | |
| Abbvie INC. | $169.68 | 2021 | |
| Amarin Pharma, INC. | $165.35 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $123.40 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.89 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $97.55 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chlebowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.